Research programme: anticancer antibodies - Roche/Xencor

Drug Profile

Research programme: anticancer antibodies - Roche/Xencor

Alternative Names: Research programme: anticancer antibodies - Xencor/Roche

Latest Information Update: 29 Apr 2008

Price : $50

At a glance

  • Originator Roche; Xencor
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 04 Jan 2006 Xencor and Roche have extended their collaborative research agreement to co-develop anticancer antibodies for Cancer
  • 12 Jan 2005 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top